Europe's Top 10 Healthtech Fundraisers in 2025 Highlight AI Advances

In 2025, Europe’s healthtech industry demonstrated robust funding momentum, as investment capital continued to flow into companies at the intersection of biotechnology, medtech, digital health, and artificial intelligence. The region saw a strong concentration of large funding rounds, highlighting sustained investor confidence in both consumer-oriented health platforms and advanced life sciences.

The United Kingdom emerged as the continent’s most active market, with high-profile rounds spanning AI-driven drug discovery, biotech innovation, surgical robotics, and digital diagnostics. Switzerland, Germany, the Netherlands, France, Spain, and Nordic countries also played significant roles in shaping the continental funding landscape.

Funding rounds in 2025 reflected a blend of early-stage Series A investments and larger growth deals. Series A activities focused on clinical and platform development, while Series B and later rounds supported companies on the path to commercialisation and international expansion.

Below are the ten European healthtech entities that raised the most capital in 2025:

Oura Health (Finland) — $900 million
Oura Health, developer of the Oura Ring smart wearable, raised over $900 million, valuing the firm at approximately $11 billion. The company focuses on continuous biometric tracking and plans to invest new capital in artificial intelligence capabilities, product development, and expanding its global reach.

Isomorphic Labs (UK) — $600 million
Spin-out from DeepMind, Isomorphic Labs leverages advanced AI—including machine learning models inspired by AlphaFold—to accelerate drug discovery. The company’s $600 million round reflects continued industry interest in AI-driven approaches to medicine design.

Verdiva Bio (UK) — $411 million
Verdiva Bio develops therapies for obesity and cardiometabolic disorders, employing innovations in gut–brain biology. Its $411 million Series A round will advance a portfolio of oral and injectable treatments.

Tubulis (Germany) — €308 million
Tubulis raised €308 million to expand its pipeline of antibody-drug conjugates for cancer treatment. The company uses proprietary technology to target tumours with increased precision, aligning with the ongoing trend of precision medicine.

Neko Health (Sweden) — $260 million
Neko Health focuses on preventative medicine with advanced scanning systems integrating AI for early disease detection. The $260 million Series B will support the rollout of non-invasive, AI-driven body scan services.

Ortivity (Germany) — €200 million
Munich-based Ortivity received €200 million to scale a physician-led, digitally integrated network of outpatient orthopaedic centres, aiming to modernise musculoskeletal care.

CMR Surgical (UK) — $200 million
Developer of the Versius robotic surgical system, CMR Surgical secured over $200 million to fund its global expansion and product innovation—particularly as the company enters the United States market.

Cera (UK) — $150 million
Cera, a digital-first home healthcare platform, combines a network of carers and nurses with AI-powered tools to improve service delivery. Its $150 million round is intended for platform expansion and operational growth.

Distalmotion (Switzerland) — $150 million
Distalmotion develops the DEXTER robotic surgery system and raised $150 million to support wider US deployment and product development, facilitating broader access to robotic-assisted surgery in hospitals.

Azafaros (Netherlands/Switzerland) — €132 million
Azafaros is developing therapies for rare genetic and metabolic disorders, completing a €132 million Series B to advance its lead candidate targeting lysosomal storage diseases.

Overall, 2025 marked a year of maturation for European healthtech, with funding supporting clear advances in AI-enabled health solutions, precision medicine, and preventative care.

Source: tech.eu